Cam Gallagher Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Cam Gallagher is President, Interim CFO of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 633,680 shares of ZNTL, which is worth approximately $2.6 Million. The most recent transaction as insider was on Feb 10, 2022, when has been sold 15,798 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 634K

0% 3M change

36.72% 12M change

Total Value Held $2.6 Million

Cam Gallagher Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 10 2022	BUY Grant, award, or other acquisition	-	15,798 Added 3.77%	403,001 Common Stock
Feb 07 2022	SELL Open market or private sale	$535,400 $53.54 p/Share	10,000 Reduced 2.52%	387,203 Common Stock
Jan 18 2022	SELL Open market or private sale	$630,500 $63.05 p/Share	10,000 Reduced 2.46%	397,203 Common Stock
Jan 05 2022	SELL Open market or private sale	$760,700 $76.07 p/Share	10,000 Reduced 2.4%	407,203 Common Stock
Dec 15 2021	SELL Open market or private sale	$752,000 $75.2 p/Share	10,000 Reduced 2.34%	417,203 Common Stock
Dec 06 2021	SELL Open market or private sale	$713,300 $71.33 p/Share	10,000 Reduced 2.29%	427,203 Common Stock
Nov 15 2021	SELL Open market or private sale	$758,200 $75.82 p/Share	10,000 Reduced 2.24%	437,203 Common Stock
Nov 05 2021	SELL Open market or private sale	$829,500 $82.95 p/Share	10,000 Reduced 2.19%	447,203 Common Stock
Oct 01 2021	SELL Open market or private sale	$661,500 $66.15 p/Share	10,000 Reduced 2.14%	457,203 Common Stock
Sep 01 2021	SELL Open market or private sale	$676,200 $67.62 p/Share	10,000 Reduced 2.1%	467,203 Common Stock
Aug 02 2021	SELL Open market or private sale	$518,400 $51.84 p/Share	10,000 Reduced 2.05%	477,203 Common Stock
Jul 07 2021	SELL Open market or private sale	$120,987 $47.04 p/Share	2,572 Reduced 0.51%	499,382 Common Stock
Jul 06 2021	SELL Open market or private sale	$752,617 $47.64 p/Share	15,798 Reduced 3.14%	487,203 Common Stock
Jul 02 2021	SELL Open market or private sale	$499,500 $49.95 p/Share	10,000 Reduced 1.94%	505,573 Common Stock
Jun 01 2021	SELL Open market or private sale	$542,900 $54.29 p/Share	10,000 Reduced 1.9%	515,573 Common Stock
May 03 2021	SELL Open market or private sale	$586,700 $58.67 p/Share	10,000 Reduced 1.87%	525,573 Common Stock
Apr 06 2021	SELL Open market or private sale	$7,138 $43.26 p/Share	165 Reduced 0.03%	541,063 Common Stock
Apr 05 2021	SELL Open market or private sale	$1,241,258 $44.01 p/Share	28,204 Reduced 5.0%	535,573 Common Stock
Mar 01 2021	SELL Open market or private sale	$416,900 $41.69 p/Share	10,000 Reduced 1.74%	563,942 Common Stock
Feb 11 2021	BUY Grant, award, or other acquisition	-	13,750 Added 2.34%	573,942 Common Stock
Feb 01 2021	SELL Open market or private sale	$377,100 $37.71 p/Share	10,000 Reduced 1.75%	560,192 Common Stock
Jan 04 2021	SELL Open market or private sale	$518,800 $51.88 p/Share	10,000 Reduced 1.72%	570,192 Common Stock
Dec 08 2020	SELL Open market or private sale	$1,269,054 $56.22 p/Share	22,573 Reduced 3.74%	580,192 Common Stock
Dec 07 2020	SELL Open market or private sale	$353,806 $52.87 p/Share	6,692 Reduced 1.1%	602,765 Common Stock
Dec 04 2020	SELL Open market or private sale	$380,875 $50.96 p/Share	7,474 Reduced 1.21%	609,457 Common Stock

Also insider at

OCUP

Ocuphire Pharma, Inc. Healthcare

Cam Gallagher

President, Interim CFO

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Value

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL

Account